Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
REGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$666.25 - $1,211.20
Previous CloseN/A
Volume208.99K
Average Volume (3M)899.66K
Market Cap
$76.33B
Enterprise Value$115.06B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)16.7
Beta0.73
Next Earnings
Feb 04, 2025EPS Estimate
11.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)40.41
Shares Outstanding108,072,390
10 Day Avg. Volume1,041,570
30 Day Avg. Volume899,658
Standard Deviation0.09
R-Squared0.00319
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.36
Price to Cash Flow (P/CF)14.40
P/FCF Ratio17.70
Enterprise Value/Market Cap1.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.18
Enterprise Value/Ebitda23.82
Forecast
1Y Price Target
$975.17Price Target Upside46.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
New Drug DevelopmentsRegeneron has a number of pipeline catalysts to watch, including potentially best-in-class drugs in oncology and other promising opportunities.
Product LaunchEylea HD pre-filled syringe application has been filed and is on track to launch in the US, potentially leveling the playing field versus Roche's Vabysmo.
Product PerformanceThe Dupixent COPD launch is off to a successful start with coverage secured from top commercial and Medicare payers.
Bears Say
Market CompetitionUS Eylea franchise estimates are being cut due to biosimilar pressure and current HD uptake constraints.
Revenue DeclineEylea revenue decline could continue, with significantly lowered overall Eylea franchise estimates reflecting competition.
Sales PerformanceEylea HD 4Q US sales were below expectations, with sales of $305 million compared to estimates of $429 million and $416 million.
---
Ownership Overview
1.95% Insiders
33.40% Mutual Funds
0.37% Other Institutional Investors
38.98% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $666.25 and its highest was $1211.20 in the past 12 months.
What is Regeneron’s market cap?
Regeneron’s market cap is $76.33B.
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Feb 04, 2025 which is yesterday.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Oct 31, 2024. The company reported $12.46 earnings per share for the quarter, beating the consensus estimate of $11.695 by $0.765.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron does not currently pay dividends.
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is 11.23.
How many shares outstanding does Regeneron have?
Regeneron has 108,072,390 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $12.46 in its last earnings report, beating expectations of $11.695. Following the earnings report the stock price went down -9.167%.
Which hedge fund is a major shareholder of Regeneron?
Among the largest hedge funds holding Regeneron’s share is Dodge & Cox. It holds Regeneron’s shares valued at 2B.
---
Regeneron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$975.17 (46.24% Upside)
$975.17 (46.24% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 56.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.73%
12-Months-Change
Fundamentals
Return on Equity
15.87%
Trailing 12-Months
Asset Growth
16.41%
Trailing 12-Months
Company Description
Regeneron
Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.
---
REGN Company Deck
---
REGN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook driven by strong revenue growth and successful product performances, particularly Dupixent and EYLEA HD. However, there are challenges due to market competition and pricing pressures. Overall, the sentiment is cautiously optimistic, with significant growth opportunities anticipated in 2025.Read More>---
REGN Revenue Breakdown
44.87% EYLEA - U.S.
28.97% Sanofi
11.34% Bayer
4.11% Libtayo - U.S.
10.72% Other
---
REGN Stock 12 Month Forecast
Average Price Target
$975.17
▲(46.24% Upside)
Technical Analysis
Best Analysts Covering REGN
1 Year
1 Year Success Rate
28/42 ratings generated profit
1 Year Average Return
+14.86%
assigned a buy rating 7 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +14.86% per trade.
---